Senhwa Biosciences is focused on addressing highly unmet medical needs in cancer treatment and is committed to developing first-in-class, breakthrough innovative therapies. Leveraging a management team with extensive experience in global pharmaceutical development and clinical execution, the Company has successfully advanced two novel drug candidates with differentiated mechanisms of action that address critical gaps in current cancer immuno-oncology therapies.
CX-5461 (Pidnarulex): An FDA Fast Track–designated G-quadruplex stabilization platform that redefines the therapeutic paradigm for cancers with high unmet medical needs.
CX-4945 (Silmitasertib): A CK2-centric, host-directed therapy that reshapes contemporary strategies for innovation in cancer and antiviral treatment.
Both core assets have received recognition from the U.S. National Cancer Institute (NCI), multiple multinational pharmaceutical companies, and Google AI. Through strong international validation and strategic collaborations, Senhwa continues to build a globally competitive platform for innovative oncology therapeutics.
